(Q38154164)

29 August 2017

title

Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment (English)

1 reference

Maria Jose Mendes Giannini

29 August 2017

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

F P Gullo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

S A Rossi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

J de C O Sardi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

V L I Teodoro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

A M Fusco-Almeida

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

4 July 2013

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

29 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

1377-1391

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json

The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of 236 autopsied cases in mumbai, India

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Mortality due to systemic mycoses as a primary cause of death or in association with AIDS in Brazil: a review from 1996 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Subcutaneous cryptococcosis due to Cryptococcus diffluens in a patient with sporotrichoid lesions case report, features of the case isolate and in vitro antifungal susceptibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Non-neoformans cryptococcal infections: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Glucuronoxylomannan from Cryptococcus neoformans down-regulates the enzyme 6-phosphofructo-1-kinase of macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Cryptococcus neoformans carried by Odontomachus bauri ants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Molecular typing of IberoAmerican Cryptococcus neoformans isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

MALDI-TOF MS enables the rapid identification of the major molecular types within the Cryptococcus neoformans/C. gattii species complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Serotyping of 467 Cryptococcus neoformans isolates from clinical and environmental sources in Brazil: analysis of host and regional patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Isolation of Cryptococcus neoformans in dry droppings of captive birds in Santiago, Chile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Occurrence of Cryptococcus neoformans in pigeon excrement in the city of Pelotas, State of Rio Grande do Sul

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Most cases of cryptococcal meningitis in HIV-uninfected patients in Vietnam are due to a distinct amplified fragment length polymorphism-defined cluster of Cryptococcus neoformans var. grubii VN1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Risk factors for Cryptococcus gattii infection, British Columbia, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Autochthonous and dormant Cryptococcus gattii infections in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Cryptococcus gattii meningoencephalitis in an immunocompetent person 13 months after exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

The expanding host tree species spectrum of Cryptococcus gattii and Cryptococcus neoformans and their isolations from surrounding soil in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Genotypes of Cryptococcus neoformans and Cryptococcus gattii as agents of endemic cryptococcosis in Teresina, Piauí (northeastern Brazil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

First case of human cryptococcosis due to Cryptococcus neoformans var. gattii in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Infections due to non-neoformans cryptococcal species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Cryptococcus laurentii fungemia in a premature neonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Pneumonia and pleural effusion due to Cryptococcus laurentii in a clinically proven case of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Fungaemia due to Cryptococcus laurentii as a complication of immunosuppressive therapy--a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Intraspecies diversity of Cryptococcus albidus isolated from humans as revealed by sequences of the internal transcribed spacer regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

First case of feline systemic Cryptococcus albidus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Cryptococcus albidus infection in a California sea lion (Zalophus californianus).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Cryptococcus spp isolated from dust microhabitat in Brazilian libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Managing cryptococcosis in the immunocompromised host

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Systemic antifungals. Pharmacodynamics and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Antifungal drug resistance of pathogenic fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Phenotypic switching in Cryptococcus neoformans contributes to virulence by changing the immunological host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Preventing antimalarial drug resistance through combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Antifungal drug resistance mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

The contribution of melanin to microbial pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Surface-active fungicidal D-peptide inhibitors of the plasma membrane proton pump that block azole resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Efflux-mediated antifungal drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Efflux pumps in drug resistance of Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Three-dimensional model of lanosterol 14 alpha-demethylase from Cryptococcus neoformans: active-site characterization and insights into azole binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Mechanisms of azole resistance in a clinical isolate of Candida tropicalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Rapid detection of triazole antifungal resistance in Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Heteroresistance of Cryptococcus gattii to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Resistance of Candida species to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Regulation of multidrug resistance in pathogenic fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Fungal Biofilms: Relevance in the Setting of Human Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Candida biofilm: a well-designed protected environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Mechanisms of biofilm resistance to antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

EDTA inhibits biofilm formation, extracellular vesicular secretion, and shedding of the capsular polysaccharide glucuronoxylomannan by Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

The use of chitosan to damage Cryptococcus neoformans biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Temperature affects the susceptibility of Cryptococcus neoformans biofilms to antifungal agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Activity of micafungin against Candida biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Screening for antimicrobial activity of ten medicinal plants used in Colombian folkloric medicine: a possible alternative in the treatment of non-nosocomial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Antifungal activity of Brazilian medicinal plants involved in popular treatment of mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Drug discovery prospect from untapped species: indications from approved natural product drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Antifungal activity of maytenin and pristimerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Quinolinyl and quinolinyl N-oxide chalcones: synthesis, antifungal and cytotoxic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Larvicidal, antimicrobial and brine shrimp activities of extracts from Cissampelos mucronata and Tephrosia villosa from coast region, Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Root cultures of Hypericum perforatum subsp. angustifolium elicited with chitosan and production of xanthone-rich extracts with antifungal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Berberine synergy with amphotericin B against disseminated candidiasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Synergic effect of grape seed extract with amphotericin B against disseminated candidiasis due to Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Structural and functional characterization of the porcine proline-rich antifungal peptide SP-B isolated from salivary gland granules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Susceptibility of Cryptococcus neoformans to photodynamic inactivation is associated with cell wall integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Cryptococcus gattii: in vitro susceptibility to photodynamic inactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Immunotherapy of Cryptococcus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Vaccine potential of cytosolic proteins loaded fibrin microspheres of Cryptococcus neoformans in BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Treatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Chemical and biological evaluation of essential oils from two species of Myrtaceae - Eugenia uniflora L. and Plinia trunciflora (O. Berg) Kausel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Antimicrobial sesquiterpenoids from Laurus nobilis L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Chemical and antifungal investigations of six Lippia species (Verbenaceae) from Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Molecular epidemiology of clinical and environmental isolates of theCryptococcus neoformansspecies complex reveals a high genetic diversity and the presence of the molecular type VGII mating type a in Colombia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-013-1915-8

Current and future therapy of invasive fungal infections.

21 January 2018

1 reference

12 December 2020

The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis

1 reference

12 December 2020

[Avian habitats as sources of Cryptococcus neoformans in the city of Campo Grande, Mato Grosso do Sul, Brazil]

1 reference

12 December 2020

Isolation of the volatile fraction from Apium graveolens L. (Apiaceae) by supercritical carbon dioxide extraction and hydrodistillation: chemical composition and antifungal activity.

1 reference

12 December 2020

Cryptococcus neoformans isolated from human dwellings in Rio de Janeiro, Brazil: an analysis of the domestic environment of AIDS patients with and without cryptococcosis

1 reference

12 December 2020

[Antifungal activity of the novel adduct, GX-95, of silver with nanometer-scale particles to peptidic hydrolysates from collagen]

1 reference

12 December 2020

The effects of jatrophane derivatives on the reversion of MDR1- and MRP-mediated multidrug resistance in the MDA-MB-231 (HTB-26) cell line.

1 reference

12 December 2020

Protective murine monoclonal antibodies to Cryptococcus neoformans

1 reference

12 December 2020

Fungemia in a cancer patient caused by fluconazole-resistant Cryptococcus laurentii

1 reference

12 December 2020

Mechanisms of resistance to azole antifungals.

1 reference

12 December 2020

Central venous catheter infections

1 reference

12 December 2020

[Present and future of voriconazole in the treatment of invasive mycoses: the inseparable binomial diagnosis-treatment]

1 reference

12 December 2020

Recent advances in the study of antifungal lead compounds with new chemical scaffolds

1 reference

12 December 2020

First environmental isolation of Cryptococcus gattii serotype B, from Cúcuta, Colombia.

1 reference

12 December 2020

Antifolates inhibit Cryptococcus biofilms and enhance susceptibility of planktonic cells to amphotericin B

1 reference

12 December 2020

Antimicrobial polyacetylenes from Panax ginseng hairy root culture

1 reference

12 December 2020

IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans

1 reference

12 December 2020

Cryptococcus gattii: An Emerging Cause of Fungal Disease in North America

1 reference

12 December 2020

The third age of antimicrobial therapy

1 reference

12 December 2020

Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans

1 reference

12 December 2020

Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans

1 reference

12 December 2020

Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.

1 reference

12 December 2020

Reversal of efflux mediated antifungal resistance underlies synergistic activity of two monoterpenes with fluconazole.

1 reference

12 December 2020

Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings

1 reference

12 December 2020

Emergence of Cryptococcus gattii-- Pacific Northwest, 2004-2010.

1 reference

12 December 2020

The use of biodiversity as source of new chemical entities against defined molecular targets for treatment of malaria, tuberculosis, and T-cell mediated diseases--a review.

1 reference

12 December 2020

Combination antifungal therapy

1 reference

12 December 2020

[Investigation of inflammatory responses of pulmonary microvascular endothelial cells induced by lipopolysaccharide and mechanism]

1 reference

12 December 2020

Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil

1 reference

12 December 2020

Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells

1 reference

12 December 2020

Synergy, antagonism, and what the chequerboard puts between them

1 reference

12 December 2020

In vitro photodynamic inactivation of Cryptococcus neoformans melanized cells with chloroaluminum phthalocyanine nanoemulsion

1 reference

12 December 2020

[The resistance of opportunistic fungi to antifungals]

1 reference

12 December 2020

In vitro antifungal activities of longan (Dimocarpus longan Lour.) seed extract

1 reference

12 December 2020

Combined effects of IL-12 and IL-18 on the clinical course and local cytokine production in murine pulmonary infection with Cryptococcus neoformans

1 reference

12 December 2020

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

1 reference

12 December 2020

Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies

1 reference

12 December 2020

The Discovery of Creatinine Assimilation in Cryptococcus neoformans, and Subsequent Work on the Characterization of the Two Varieties of C. neoformans

1 reference

12 December 2020

Amphotericin B: 30 years of clinical experience

1 reference

12 December 2020

Proanthocyanidin-rich extracts from cranberry fruit (Vaccinium macrocarpon Ait.) selectively inhibit the growth of human pathogenic fungi Candida spp. and Cryptococcus neoformans

1 reference

12 December 2020

Molecular biological characterization of an azole-resistant Candida glabrata isolate

1 reference

12 December 2020

Cryptococcosis due to Cryptococcus neoformans var. gattii in Brazilian patients with AIDS. Report of three cases

1 reference

12 December 2020

Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis

1 reference

12 December 2020

Antimicrobial activity of Pterogyne nitens Tul., Fabaceae, against opportunistic fungi

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.1590/S0102-695X2010005000017

Identifiers

DOI

10.1007/S10096-013-1915-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 June 2020

1013096966

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24141976%20AND%20SRC:MED&resulttype=core&format=json